Ulcerative colitis. Ulcerative colitis
Conditions
Interventions
Treatment - Other
Placebo
Intervention 1: Intervention group: Daily intake of two CoQ10 capsules (100 mg) for 8 weeks (2 months). Intervention 2: Control group: Daily intake of two placebo capsules (containing rice flour) for
Intervention group: Daily intake of two CoQ10 capsules (100 mg) for 8 weeks (2 months).
Control group: Daily intake of two placebo capsules (containing rice flour) for 8 weeks (2 months)
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: The willingness to voluntarily participate in the study The definitive diagnosis of ulcerative colitis by using histological studies of mucosal colon, rectum, and jejunium biopsy by the physician in the mild to moderate phase, The consumer of only one of the drug groups 5 -Amino salicylic acid (Pentasa, Mesalazine or Asacol), as well as azathioprine An age 18 and above BMI greater than 18.5 and less than 30 Each of the two sexes
Exclusion criteria
Exclusion criteria: Changing the type and dosage of the drug over the past month The incidence of other autoimmune diseases, cancer Pregnancy or lactation in women The use of multi vitamin-mineral supplements, antioxidants, and also the use of anticoagulants, blood cholesterol lowering drugs, anti-TNF drugs, and glucocorticosteroids over the past month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-10. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of IL-10 in serum using ELISA kit.;IL-17. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of IL-17 in serum using ELISA kit.;NF-kB. Timepoint: Before the intervention and two months later of intervention. Method of measurement: NF-kB activity in peripheral blood cells.;Nrf2. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Nrf2 activity in peripheral blood cells.;HBD2. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of hBD2 in serum using ELISA kit.;Cathelicidin LL-37. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Concentration of cathelicidin LL-37 in serum using ELISA kit.;MicroRNA-146a. Timepoint: Before the intervention and two months later of intervention. Method of measurement: microRNA-146a expression levels in serum using kit.;Quality of Life. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the IBDQ-9 questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the ratio of weight (kilogram) to the square of height (meter).;Weight. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Using the digital scale.;Waist circumference. Timepoint: Before the intervention and two months later of intervention. Method of measurement: Distance of the last rib with iliac bone using tape meter.;Hip circumference. Timepoint: ??? ?? ???? ?????? ? ?? ??? ??? ?? ???? ??????. Method of measurement: The largest hip circumference using the tape meter.;Waist–hip ratio. Timepoint: Before the intervention and two months later of intervention. Method of measurement: The result of dividing the waist circumference into the hip circumference. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Vafa
Iran University of Medical Sciences
Outcome results
None listed